Back to top
more

BioLife Solutions (BLFS)

(Real Time Quote from BATS)

$20.56 USD

20.56
45,993

-0.33 (-1.58%)

Updated Aug 5, 2025 10:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts

by Zacks Equity Research

ENSG adds Idaho and Texas facilities to its skilled nursing facility and real estate portfolios and earns an opportunity to boost revenues by catering to growing patient volumes.

Zacks Equity Research

Encompass Health Plans a 50-Bed Unit to Better Serve North Las Vegas

by Zacks Equity Research

EHC unveils plans for a 50-bed rehabilitation hospital in North Las Vegas, bringing improved health outcomes to the region's residents and further solidifying its Nevada footprint.

Zacks Equity Research

How Much Upside is Left in BioLife Solutions (BLFS)? Wall Street Analysts Think 41.72%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 41.7% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

EHC Opens Rehabilitation Unit in Fort Myers, Boosts Florida Footprint

by Zacks Equity Research

Encompass Health inaugurates the Rehabilitation Hospital of Fort Myers in partnership with Lee Health to provide high-quality rehabilitation services across Florida.

Zacks Equity Research

Can BioLife Solutions (BLFS) Climb 30.68% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 30.7% upside potential for BioLife Solutions (BLFS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

BioLife Solutions, Inc. (BLFS) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

BioLife Solutions (BLFS) delivered earnings and revenue surprises of 233.33% and 5.28%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Green Thumb Industries Inc. (GTBIF) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Green Thumb Industries Inc. (GTBIF) delivered earnings and revenue surprises of -20% and 2.01%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of 0.42% and 0.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Insulet (PODD): Can Its 7.2% Jump Turn into More Strength?

by Zacks Equity Research

Insulet (PODD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Aparajita Dutta headshot

5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes

by Aparajita Dutta

The crux of safe investment lies in choosing a company that is not burdened with debt. You may buy BLFS, WLDN, NXT, NVO and EZPW

Aparajita Dutta headshot

5 Low-Leverage Stocks to Buy Amid Volatile Market Sentiment

by Aparajita Dutta

The crux of safe investment lies in choosing a company that is not burdened with debt. You may buy BLFS, BHLB, NVDA, GBX and EZPW.

Zacks Equity Research

BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioLife Solutions (BLFS) delivered earnings and revenue surprises of 83.33% and 6.29%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Recent Price Trend in BioLife Solutions (BLFS) is Your Friend, Here's Why

by Zacks Equity Research

BioLife Solutions (BLFS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

BioLife Solutions, Inc. (BLFS) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

BioLife Solutions (BLFS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Strong Segmental Performance to Drive Stryker's Q4 Earnings?

by Zacks Equity Research

SYK's fourth-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Zacks Equity Research

Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how BioLife Solutions, Inc. (BLFS) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year.

Zacks Equity Research

BioLife Solutions (BLFS) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, BioLife Solutions (BLFS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioLife Solutions (BLFS) delivered earnings and revenue surprises of 77.78% and 21.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Canopy Growth Corporation (CGC) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Canopy Growth (CGC) delivered earnings and revenue surprises of -150% and 1.42%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year?

by Zacks Equity Research

Here is how BioLife Solutions, Inc. (BLFS) and Eli Lilly (LLY) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why Momentum in BioLife Solutions (BLFS) Should Keep going

by Zacks Equity Research

BioLife Solutions (BLFS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Are Medical Stocks Lagging Eli Lilly (LLY) This Year?

by Zacks Equity Research

Here is how Eli Lilly (LLY) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.

Zacks Equity Research

Here's What Could Help BioLife Solutions (BLFS) Maintain Its Recent Price Strength

by Zacks Equity Research

BioLife Solutions (BLFS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year?

by Zacks Equity Research

Here is how BioLife Solutions, Inc. (BLFS) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.

Zacks Equity Research

BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioLife Solutions (BLFS) delivered earnings and revenue surprises of 57.14% and 19.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?